Arbutus Biopharma Corp
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M |
| Operating expenses | $52.2M | $82.5M | $96.2M | $104.5M | $84.5M |
| Cash from operations | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M |
| Capital expenditure | $0 | $182,000 | $1.0M | $512,000 | $809,000 |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M |
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M |
Shares outstanding 197.5M · Free float 60.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.